BioMoti is a cancer therapeutics co-development company. This means we work collaboratively with selected strategic partners to improve cancer patient outcomes. Our core technology enables us to simultaneously neutralize a key tumour immuno-evasion mechanism and precisely deliver active anti-cancer agents to tumours. This is the Oncojan™ therapeutics platform, bioengineered drug-loaded microparticles surface-modified with CD95R. Oncojan™ is compatible with many classes of drugs including small molecules and larger biologicals (peptides, proteins and nucleic acids). Oncojans™ have the potential to be transformational in the treatment of cancer patients. They offer the opportunity to increase the efficacy of marketed drugs and improve their safety profile. The technology can also be combined with new drugs in development or to re-test shelved drugs that may previously have failed due to toxicity or delivery issues.
BioMoti actively seeks co-development partnerships with established drug developers. We offer a flexible and tiered partnership structure starting with low-cost/low-risk feasibility projects to flexible co-development/out-licensing agreements. This enables partners to build confidence in our innovative precise immunotherapeutic nanomedicine platform prior to negotiating a long-term agreement. Please contact us if you have an active oncology compound that would benefit from targeted access to the intracellular space and an improved therapeutic window or are interested in our pipeline candidates.
Interested in partnering with BioMoti?
BioMoti is always looking for partners to push forward therapeutic candidates and overcome one of the world's biggest killers, cancer.
If you would like more information,
please contact us.